Santen Pharmaceutical Co Ltd
TSE:4536
Santen Pharmaceutical Co Ltd
Operating Income
Santen Pharmaceutical Co Ltd
Operating Income Peer Comparison
Competitive Operating Income Analysis
Latest Figures & CAGR of Competitors
Company | Operating Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Santen Pharmaceutical Co Ltd
TSE:4536
|
Operating Income
¥49B
|
CAGR 3-Years
16%
|
CAGR 5-Years
3%
|
CAGR 10-Years
6%
|
|
Takeda Pharmaceutical Co Ltd
TSE:4502
|
Operating Income
¥464.9B
|
CAGR 3-Years
7%
|
CAGR 5-Years
18%
|
CAGR 10-Years
17%
|
|
Daiichi Sankyo Co Ltd
TSE:4568
|
Operating Income
¥188B
|
CAGR 3-Years
37%
|
CAGR 5-Years
19%
|
CAGR 10-Years
5%
|
|
Otsuka Holdings Co Ltd
TSE:4578
|
Operating Income
¥294.7B
|
CAGR 3-Years
13%
|
CAGR 5-Years
32%
|
CAGR 10-Years
3%
|
|
Chugai Pharmaceutical Co Ltd
TSE:4519
|
Operating Income
¥444.2B
|
CAGR 3-Years
14%
|
CAGR 5-Years
29%
|
CAGR 10-Years
19%
|
|
Astellas Pharma Inc
TSE:4503
|
Operating Income
¥142B
|
CAGR 3-Years
-5%
|
CAGR 5-Years
-12%
|
CAGR 10-Years
3%
|
See Also
What is Santen Pharmaceutical Co Ltd's Operating Income?
Operating Income
49B
JPY
Based on the financial report for Dec 31, 2023, Santen Pharmaceutical Co Ltd's Operating Income amounts to 49B JPY.
What is Santen Pharmaceutical Co Ltd's Operating Income growth rate?
Operating Income CAGR 10Y
6%
The average annual Operating Income growth rates for Santen Pharmaceutical Co Ltd have been 16% over the past three years , 3% over the past five years , and 6% over the past ten years .